Verismo Therapeutics Announces $17 million in a Second Pre-Series A with DongKoo Bio, HLB Innovation, and HLB as Lead Investors
18 Jul 2023
ImmunotherapyCell TherapyPhase 1IND
Verismo Therapeutics has raised a total of $50M since launching
PHILADELPHIA, July 18, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced it has raised $17M in a second pre-Series A financing round. The financing will support continued advancement of the clinical trial for SynKIR™-110, a first-in-class KIR-CAR T cell immunotherapy candidate for solid tumors, and pre-clinical development of SynKIR™-310, a KIR-CAR T cell immunotherapy therapeutic for blood cancers.
The funding round was co-led by DongKoo Bio, HLB Innovation and HLB. The funding will be used to advance multiple programs targeting solid and liquid tumors. With this $17M investment Verismo will have secured a total of $50M in financing since launching in 2020.
About the KIR-CAR Platform
The KIR-CAR platform is a dual-chain CAR T cell therapy and has been shown in preclinical animal models to be capable of maintaining antitumor T cell activity even in challenging solid tumor environments. DAP12 acting as a novel costimulatory molecule for T cells, aids additional T cell stimulating pathways, further sustaining chimeric receptor expression and improving KIR-CAR T cell persistence. This continued T cell function and persistence can lead to ongoing regression of solid tumors in preclinical models, including those refractory to traditional CAR T cell therapies. Furthermore, the KIR-CAR platform can be combined with many additional emerging technologies, such as in vivo gene engineering, advanced cell manufacturing and reprogramming, combinational therapies, and even allogeneic cellular therapies to provide the next-generation multimodal targeted immunotherapy for patients in need.
About Verismo Therapeutics
Verismo Therapeutics is a pioneer in dual-chain KIR-CAR technology, and its lead asset, SynKIR™-110, is currently undergoing first-in-human Phase 1 clinical trial. Verismo is the only company developing the KIR-CAR T cell platform, a modified NK-like receptor designed to improve persistence and efficacy against aggressive solid tumors. The KIR-CAR T cell platform technology was developed specifically for advanced solid tumors, an area of high unmet medical need. For more information, visit: .
Media contact: Alyson Kuritz, alyson@0to5.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.